WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the first patient has been enrolled and dosed in its Phase Ib clinical trial in advanced solid tumors, which combines its lead Vascular Disrupting Agent (VDA), CA4P, with an antiangiogenic agent, bevacizumab (Avastin). In a recent Science (Shaked, et al, 2006) publication, the combination of a VDA with an antiangiogenic agent was described as offering a powerful and highly targeted regimen for suppressing tumor growth. Dr. Richard Chin, President and CEO of OXiGENE, stated, “We are very excited to begin enrollment in this important trial. We believe that the combination of CA4P and Avastin has the potential to bring significant benefit to patients. This patient enrollment also highlights our renewed focus on executing our programs rapidly and on schedule.” OXiGENE believes that this dose escalation trial is the first step toward fully elucidating the efficacy and safety profiles of combining VDAs and antiangiogenic agents in patients.
